BenevolentAI, the British-based technology company which uses artificial intelligence to aid the drug discovery process, is close to securing a major strategic investment from Eli Lilly, the global pharmaceutical giant.
Sky News has learnt that Eli Lilly is likely to participate in a new fundraising being finalised by BenevolentAI alongside a number of new and existing investors.
Sources said the funding round could secure in the region of $75m of new capital for the company. Image: Eli Lilly is likely to participate in a new fundraising, Sky News has learned
The valuation at which the new equity would be injected was unclear on Friday.